Avacta Group PLC on Thursday revealed it has expanded its oncology pipeline with two novel preclinical assets.
AVA6103 and AVA7100 were developed utilising Avacta’s precision platform which works to optimise dosing in the tumour environment and improve outcomes for cancer patients.
These new assets will add value to the AIM-listed life sciences company’s portfolio of precision candidates developed for ‘reducing systemic toxicities’ and ‘improving antitumour activity’ when activated in the tumour environment.
The latter candidate, AVA1700, represents a new class of oncology treatments under development by the UK-based business with potential for use across multiple cancer types. It works through a process of engineered molecular bonding, similar to how an antibody binds to its target, but with reduced ‘molecule size and greater binding affinity’.
By contrast, AVA6103 works by delivering an exatecan payload - a potent inhibitor which has demonstrated clinical activity in a variety of cancers - direct to tumours whilst minimising normal tissue exposure.
Chief Executive Officer Christina Coughlin stated: ‘The expansion of our pipeline highlights the broad potential of our proprietary precision technology to deliver multiple potent oncology therapeutics directly into difficult-to-treat tumours, while sparing healthy tissues.
‘These novel assets have been carefully selected to complement our existing portfolio, by targeting cancers with high unmet need and having clear development strategies. We look forward to sharing data across our programs in the near future.’
Shares in Avacta business rose 4.9% to 67.75 pence in early afternoon trading in London on Thursday.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
